CompoAtlas

ROSE BEAUTY DRINK

Food supplement declared in France, decision dated 21 August 2026

ROSE BEAUTY DRINK is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). 1 point in its composition requires a check (prohibited substance, dose or novel food). 2 rules of use apply to its ingredients (limits and warnings).

Brand
not provided
Food business operator placing the product on the market
L'ILE ZEN HEALING
Status
Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
Form
Ampoule
Daily dose
1 ampoule
Intended populations
Hommes et femmes de 18 ans et plus
Not recommended for (according to the manufacturer)
Adolescents (moins de 18 ans), Femmes allaitantes, Femmes enceintes
Objectives stated by the manufacturer (these are not authorised claims)
Peau, Cheveux et ongles

Declaration 361625, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.

Regulatory points

Declared composition

Plants

PlantPartPreparationPer day
Rosadamascena Herrm.FleurHydrolât (eau florale)300 mg
Rosa centifolia L.PétalesExtrait sec aqueux120 mg
Rosa canina L.FruitExtrait sec hydroalcoolique120 mg
Valeriana officinalis L.RacineExtrait sec aqueux30 mg
Phyllanthus emblica L.FruitExtrait sec aqueux30 mg
Borago officinalis L.Graine (huile)Pression à froid20 mg
Viola tricolor L.Parties aériennesExtrait sec aqueux20 mg
Vaccinium myrtillus L.FruitExtrait sec hydroalcoolique10 mg

Additives

E960, E422

Other ingredients

Rosadamascena Herrm., Rosa rugosa, eau

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Déconseillé en cas d'allergie aux dérivés salicylés.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Valeriana officinalis L.
    Read the warning, when it applies and the studies cited

    Valerian - VALERIANA OFFICINALIS

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Mills et al. 2006; Blumenthal et al. 2003; Barnes et al. 2002).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product avoid taking with alcohol or products that cause drowsiness (Brinker 2010; Gennaro et al. 2000).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2016; ESCOP 2003; Bradley 1992).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Sleep aid.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists continuously for more than 4 weeks (chronic insomnia) (EMA 2016; Berardi et al. 2002; Dipiro et al. 2002).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 26 July 2024

  • Phyllanthus emblica L.
    Read the warning, when it applies and the studies cited

    Amla - Phyllanthus Emblica

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (HC 2009).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Applies to products providing more than 3 grams of amla, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (HC 2009).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Amlapitta, Digestive tonic.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: Laxative.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (HC 2009; Pray 2006; CPhA 2002).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Condition of application: Laxative.

    Do not use if you have fever or any undiagnosed gastrointestinal trouble (HC 2009).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Condition of application: Amlapitta, Antioxidant, Digestive tonic, Rasayana or Eye tonic.

    When using this product you may experience a laxative effect.

    Health Canada monograph dated 28 March 2025

  • Borago officinalis L.
    Read the warning, when it applies and the studies cited
  • Vaccinium myrtillus L.
    Read the warning, when it applies and the studies cited

    BILBERRY - VACCINIUM MYRTILLUS - Buccal

    Route of administration: Buccal (Blumenthal et al. 2000)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 30 January 2026

    BILBERRY - VACCINIUM MYRTILLUS - Oral

    Route of administration: Oral (Blumenthal et al. 2000)

    Cautions and warnings

    Condition of application: Relief of diarrhea.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: Slowing the progression of disorders of the eye and to relieve symptoms related to non-complicated CVI.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

    Health Canada monograph dated 25 October 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line